Letters — appeals to medical and pharmaceutical professionals

DELTYBA

Information material for health care professionals on minimizing important risks associated with the use of a medicinal product for the treatment of multidrug-resistant tuberculosis in adults. It contains a list of risks (resistance, QTc interval prolongation, pregnancy, breastfeeding) and measures for their prevention. compiled automatically

CYTERAL

Information letter to healthcare professionals regarding the medicinal product CITERAL (ciprofloxacin) on the addition of a new warning concerning the risk of heart valve regurgitation/insufficiency and aortic aneurysm and dissection with the use of systemic and inhaled fluoroquinolones. compiled automatically

TIMOXI

The information letter to healthcare professionals concerning the medicinal product TIMOXI (moxifloxacin) reports the addition of a new warning about the risk of heart valve regurgitation/insufficiency and aortic aneurysm and dissection with the use of systemic and inhaled fluoroquinolones. The document contains recommendations for assessing benefit and risk and for monitoring patients in higher-risk groups. generated automatically

AVELOX®

Information letter for healthcare professionals on the risk of heart valve regurgitation and incompetence with the use of fluoroquinolones for systemic and inhaled use. Contains a description of the safety issue, risk factors, recommendations on benefit/risk assessment, and the procedure for reporting adverse reactions. compiled automatically

LEMTRADA/update

Information letter to healthcare professionals on new safety data for an alemtuzumab-based product obtained in the post-registration period. Contains a description of identified risks (liver injury, cardiovascular and immune-mediated reactions) and measures to minimize them. compiled automatically

POMALIDOMIDE-VISTA

Informational letter to healthcare professionals on minimizing the risks of teratogenicity, hepatotoxicity, interstitial lung disease, and heart failure when using a pomalidomide-based medicinal product for the treatment of multiple myeloma. Contains recommendations on safety monitoring, contraindications, and the Pregnancy Prevention Program. compiled automatically

LEMTRADA

Eligard

LEUPRORELIN SANDOZ®

TECENTRIQ®